SBIR/STTR Research Award
Clinical trial of an innovative digital therapeutic for smoking cessation with biochemical verification
Award amount
$224,951Program and phase
SBIR · Phase IAward year
2018Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- CLICK THERAPEUTICS, INC.
- Proposal award date
- 2018-06-01
- Contract end date
- 2019-05-31
- UEI
- Not reported
- Solicitation number
- PA17-302
- Topic code
- NIDA
Research abstract
Cigarette smoking is the leading preventable cause of death in the USAlthoughout ofsmokers want to quitless thanof quit attempts remain successful one
year laterSmartphone apps are a promising method to deliver behavioral
interventions due to their immediate accessibilityreduced barriers to treatmentand high penetration of the target populationThe goal of this SBIR is to reduce the
health impact of smoking by establishing Click TherapeuticsIncs smartphone app
for smoking cessationClickotineCKTas a digital therapeutic solution to help
smokers quit with lower costreduced need for healthcare accessand fewer
adverse effects than current best alternativesCKT follows US Clinical Practice
GuidelinesUSCPGfor smoking cessation and uses interventions supported by
researchpersonalized messagingcontrolled breathingsocial engagementtreatment adherencefinancial incentivesand digital diversionsShort term quit
rates observed in a pilot clinical trial of CKT compare favorably to published results
of other smartphone apps for smoking cessationHoweverto date no such studies
have provided biochemically verified evidence for long term quit rateswhich forms
the gold standard for measuring other therapies for smokingThis project will
address this gap in knowledge through blinded randomized controlled trials
comparing CKT to another widely used USCPG smartphone appthe National Cancer
Institute s QuitGuideThis pivotal research will feature longer term follow up and
biochemical verification with feasibility established in Phase IThe results of this
study will provide the rigorous clinical evidence for the efficacy and safety of CKT
necessary for its successful commercialization in the digital therapeutics marketWide availability of an engaginglow cost mobile intervention to help smokers quit
with reduced healthcare usage will have substantial population level impact on
public health in the United States This proposal will generate rigorous clinical evidence for Clickotinean innovativelow cost smartphone app for smoking cessationSuccessful completion of the
research will lead to the development of an effective treatment to reduce thedeaths per year and $billion in health care costs caused by cigarette
smoking
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Wearable Wireless Respiratory Monitoring System that Detects and Predicts Opioid Induced Respiratory Depression
- Building and testing the Life Enhancement and Advocacy Programming digital training tool (LEAPLink) to better serve people with lived experience of homelessness and substance use disorder
- A digital intervention to decrease self-stigma among pregnant and postpartum women with opioid use disorder
- Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting.
- Creation and Validation of the Dose-Opioid-Source Evaluation tool (DOSE) - a Robust Opioid Use Clinical Outcome Assessment for Qualification as an FDA Medical Device Development Tool (MDDT)